Login to Your Account

U.S. Patent Disclosures

Monday, December 19, 2011
• Fate Therapeutics Inc., of San Diego, was granted U.S. Patent No. 8,044,201, titled "Stem Cell Cultures," which claims Thiazovivin, a small-molecule Rho-associated kinase inhibitor, as well as compositions and cell culture media comprising Thiazovivin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription